Read More

Akari Therapeutics Announced Updates On Progress In The Pre-clinical Development Program For Long-Acting PAS-Nomacopan As A Potential Treatment For Geographic Atrophy Secondary To Dry Age-related Macular Degeneration

Akari is targeting an Investigational New Drug application submission to the FDA in the first half of 2024. Composition of matter patent application filed on long-acting PAS-nomacopan versions, which, if granted,

AKTX

Read More

Prophase Labs’ Prophase Labs Will Acquiring New Equipment Which Is Expected To Double Its Current Capacity For Pouch Packaging By Q2 Of 2023. Pharmaloz Is Also Planning For Expansion Of Its Lozenge Manufacturing Business

Altogether, these expansion initiatives are expected to lead to a 200% increase in capacity for 2024 as compared to 2022. It is currently expected that the Pharmaloz expansion will be funded entirely from

PRPH